Opinion|Videos|May 30, 2025
Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how the PALOMA-3 study demonstrated that subcutaneous amivantamab is noninferior to intravenous (IV) administration with significantly lower infusion-related reaction (IRR) rates (13% vs 66%), shorter administration time (5 minutes vs 5 hours), higher patient-reported convenience (85% vs 35%), and improved clinical outcomes, making it potentially preferable for most eligible patients once FDA approved.
Advertisement
Episodes in this series
Subcutaneous vs IV Amivantamab
- PALOMA-3 study findings:
- Similar efficacy: 30% response rate (subcutaneous) vs 33% (IV)
- Improved PFS: 6.1 months (subcutaneous) vs 4.3 months (IV) in heavily pretreated population
- Significantly reduced IRRs: 13% (subcutaneous) vs 66% (IV)
- Fewer venous thromboembolism events with subcutaneous administration
- Operational advantages:
- Dramatically reduced administration time: 5 minutes (subcutaneous) vs 5 hours (IV)
- Improved infusion chair turnover
- No split dosing required (unlike IV which requires day 1/day 2 split)
- Patient preference: 85% rated subcutaneous as convenient vs 35% for IV
- Not yet FDA approved outside clinical trials
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5